加载中
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
前收盘价
US$5.94
−US$0.40 · -6.31%
盘后
US$5.94
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
日内区间
当前US$5.94
52周区间
当前US$5.94
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
38
偏贵
情绪
60
多空交织
风险
40
中等风险
动量
79
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
日内区间
当前US$5.94
52周区间
当前US$5.94
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|
| 营收 | 899.5万 USD | — | — | — |
| 毛利 | 899.5万 USD | — | — | — |
| 研究与开发 | 7396.6万 USD | 5903.6万 USD | 3388.6万 USD | 3052.2万 USD |
| 销售、一般及管理费用 | 2780.9万 USD | 1915.8万 USD | 1451.4万 USD | 944.7万 USD |
| 营业费用 | 1.02亿 USD | 7819.4万 USD | 4840万 USD | 3996.9万 USD |
| 利息收入 | 1308.6万 USD | 962.9万 USD | 243.1万 USD | 46.5万 USD |
| 利息支出 | 69.7万 USD | 236.7万 USD | 779.4万 USD | 24.1万 USD |
| 折旧和摊销 | 21.3万 USD | 16.7万 USD | 16.2万 USD | 12.9万 USD |
| 营业利润 | −9278万 USD | −7819.4万 USD | −4840万 USD | −3996.9万 USD |
| 净利润 | −8060.5万 USD | −7110.9万 USD | −6385.4万 USD | −3972.2万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1083.56万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM534.75万0.01%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF353.43万0.00%954亿 USD0.05%US$233.52-0.63%
Vanguard U.S. Momentum Factor ETFVFMO313.18万0.16%19亿 USD0.13%US$227.71-1.04%
State Street SPDR S&P Pharmaceuticals ETFXPH288.27万0.62%4.69亿 USD0.35%US$64.01-0.99%
Vanguard Russell 2000 ETFVTWO192.27万0.01%180亿 USD0.06%US$112.27-0.35%
iShares Biotechnology ETFIBB155.69万0.01%108.2亿 USD0.44%US$204.26-1.08%
Dimensional - US Small Cap ETFDFAS139.53万0.00%338.69亿 USD0.31%US$78.17-0.23%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard U.S. Momentum Factor ETFVFMOState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
